C

Concord Biotech Ltd
NSE:CONCORDBIO

Watchlist Manager
Concord Biotech Ltd
NSE:CONCORDBIO
Watchlist
Price: 1 396.6 INR 0.71% Market Closed
Market Cap: 146.1B INR
Section:
Relative Value
Relative Value
Valuation Multiples
Multiples Across Competitors
See Also

Relative Value

The Relative Value of one CONCORDBIO stock under the Base Case scenario is 1 202.04 INR. Compared to the current market price of 1 396.6 INR, Concord Biotech Ltd is Overvalued by 14%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

CONCORDBIO Relative Value
Base Case
1 202.04 INR
Overvaluation 14%
Relative Value
Price
C
Worst Case
Base Case
Best Case

Valuation Multiples

13.4
P/S
P/S
Price to Sales
13.4
vs History
60
vs Industry
9
Median 3Y
15.1
Median 5Y
15.1
Industry
2.4
Forward
12.3
More Details
44.8
P/E
P/E
Price to Earnings
44.8
vs History
60
vs Industry
8
Median 3Y
49.7
Median 5Y
49.7
Industry
20.3
Forward
40.8
More Details
55
P/OCF
P/OCF
Price to OCF
55
vs History
78
vs Industry
6
Median 3Y
61.8
Median 5Y
61.8
Industry
15.6
More Details
96.6
P/FCFE
P/FCFE
Price to FCFE
96.6
vs History
91
vs Industry
4
Median 3Y
126.6
Median 5Y
126.6
Industry
23.1
More Details
9.2
P/B
P/B
Price to Book Value
9.2
vs History
78
vs Industry
5
Median 3Y
10.9
Median 5Y
10.9
Industry
2
More Details
13.1
EV/S
EV/S
Enterprise Value to Sales
13.1
vs History
60
vs Industry
9
Median 3Y
14.8
Median 5Y
14.8
Industry
2.5
Forward
12
More Details
17.4
EV/GP
EV/GP
Enterprise Value to Gross Profit
17.4
vs History
60
vs Industry
10
Median 3Y
19.6
Median 5Y
19.6
Industry
4.8
More Details
31.7
EV/EBITDA
EV/EBITDA
Enterprise Value to EBITDA
31.7
vs History
65
vs Industry
9
Median 3Y
35.4
Median 5Y
35.4
Industry
12.5
Forward
29
More Details
36
EV/EBIT
EV/EBIT
Enterprise Value to EBIT
36
vs History
60
vs Industry
9
Median 3Y
39.7
Median 5Y
39.7
Industry
15.7
Forward
34.1
More Details
53.8
EV/OCF
EV/OCF
Enterprise Value to OCF
53.8
vs History
78
vs Industry
7
Median 3Y
60.8
Median 5Y
60.8
Industry
14.1
More Details
79.5
EV/FCFF
EV/FCFF
Enterprise Value to FCFF
79.5
vs History
91
vs Industry
5
Median 3Y
100.7
Median 5Y
100.7
Industry
17.6
More Details
10.5
EV/IC
EV/IC
Enterprise Value to IC
10.5
vs History
78
vs Industry
7
Median 3Y
12.2
Median 5Y
12.2
Industry
1.8
More Details

Multiples Across Competitors

CONCORDBIO Competitors Multiples
Concord Biotech Ltd Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
Market Cap P/S P/E EV/EBITDA EV/EBIT
IN
Concord Biotech Ltd
NSE:CONCORDBIO
146.1B INR 13.4 44.8 31.7 36
US
Eli Lilly and Co
NYSE:LLY
738.9B USD 15 66.2 35.7 39.1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP 578.3 -15 783.5 3 846.3 17 702.3
US
Johnson & Johnson
NYSE:JNJ
378.6B USD 4.2 17.3 12.7 16.6
DK
Novo Nordisk A/S
CSE:NOVO B
2T DKK 6.8 19.6 13 14.7
CH
Roche Holding AG
SIX:ROG
211.7B CHF 3.5 25.6 9.6 11.2
CH
Novartis AG
SIX:NOVN
180B CHF 4.1 17 10 13.4
UK
AstraZeneca PLC
LSE:AZN
162.9B GBP 4 28 130.7 197.1
US
Merck & Co Inc
NYSE:MRK
200.3B USD 3.1 11.4 8.3 9.9
IE
Endo International PLC
LSE:0Y5F
163.5B USD 70.5 -56 261.3 655.3
US
Pfizer Inc
NYSE:PFE
129.2B USD 2.1 16.4 7.1 10
P/E Multiple
Earnings Growth PEG
IN
C
Concord Biotech Ltd
NSE:CONCORDBIO
Average P/E: 27.4
44.8
22%
2
US
Eli Lilly and Co
NYSE:LLY
66.2
49%
1.4
UK
Dechra Pharmaceuticals PLC
LSE:DPH
Negative Multiple: -15 783.5 N/A N/A
US
Johnson & Johnson
NYSE:JNJ
17.3
27%
0.6
DK
Novo Nordisk A/S
CSE:NOVO B
19.6
18%
1.1
CH
Roche Holding AG
SIX:ROG
25.6
32%
0.8
CH
Novartis AG
SIX:NOVN
17
17%
1
UK
AstraZeneca PLC
LSE:AZN
28
36%
0.8
US
Merck & Co Inc
NYSE:MRK
11.4
18%
0.6
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -56 N/A N/A
US
Pfizer Inc
NYSE:PFE
16.4
29%
0.6
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
IN
C
Concord Biotech Ltd
NSE:CONCORDBIO
Average EV/EBITDA: 397
31.7
21%
1.5
US
Eli Lilly and Co
NYSE:LLY
35.7
31%
1.2
UK
Dechra Pharmaceuticals PLC
LSE:DPH
3 846.3
36%
106.8
US
Johnson & Johnson
NYSE:JNJ
12.7
8%
1.6
DK
Novo Nordisk A/S
CSE:NOVO B
13
14%
0.9
CH
Roche Holding AG
SIX:ROG
9.6
6%
1.6
CH
Novartis AG
SIX:NOVN
10
5%
2
UK
AstraZeneca PLC
LSE:AZN
130.7
9%
14.5
US
Merck & Co Inc
NYSE:MRK
8.3
9%
0.9
IE
E
Endo International PLC
LSE:0Y5F
261.3
N/A N/A
US
Pfizer Inc
NYSE:PFE
7.1
2%
3.6
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
IN
C
Concord Biotech Ltd
NSE:CONCORDBIO
Average EV/EBIT: 1 700.5
36
19%
1.9
US
Eli Lilly and Co
NYSE:LLY
39.1
33%
1.2
UK
Dechra Pharmaceuticals PLC
LSE:DPH
17 702.3
98%
180.6
US
Johnson & Johnson
NYSE:JNJ
16.6
13%
1.3
DK
Novo Nordisk A/S
CSE:NOVO B
14.7
14%
1.1
CH
Roche Holding AG
SIX:ROG
11.2
6%
1.9
CH
Novartis AG
SIX:NOVN
13.4
10%
1.3
UK
AstraZeneca PLC
LSE:AZN
197.1
21%
9.4
US
Merck & Co Inc
NYSE:MRK
9.9
12%
0.8
IE
E
Endo International PLC
LSE:0Y5F
655.3
N/A N/A
US
Pfizer Inc
NYSE:PFE
10
10%
1

See Also

Summary
CONCORDBIO intrinsic value, competitors valuation, and company profile.
DCF Valuation
CONCORDBIO stock valuation using Discount Cash Flow valuation method.
Relative Valuation
CONCORDBIO stock valuation using valuation multiples.
Wall Street Estimates
CONCORDBIO price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
CONCORDBIO stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Back to Top
ALPHA SPREAD
Follow us
Join more than 253,100+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2025 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.